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Abstract
Spinal fusion is hampered by the presence of remaining 
intervertebral disc (IVD) tissue and leads to spinal non-
union. While the exact mechanism remains unknown, we 
hypothesise that factors preventing disc ossification, such 
as antagonists of the bone morphogenetic proteins (BMP), 
could be responsible for this process.
 The objective of this study was to investigate spinal 
non-union using an in vitro human model with a focus on 
the BMP signalling components and to identify factors 
contributing to the incomplete and delayed ossification. 
Human bone marrow-derived mesenchymal stromal cells 
(MSC) were cocultured with IVD cells in the presence of 
L51P, a BMP2 variant with osteoinductive potential. The 
ossification of MSC was evaluated by quantitative reverse 
transcription polymerase chain reaction (qPCR), alkaline 
phosphatase (ALP) activity and alizarin red staining. 
Endogenous expression of major BMP antagonists, namely 
Gremlin (GREM1), Noggin (NOG) and Chordin (CHRD) 
was detected in IVD-derived cells, with abundance in 
nucleus pulposus cells. Osteogenesis of MSC was hindered 
by IVD cells as shown by reduced alizarin red staining, 
ALP activity and qPCR. L51P, added to the cocultures, 
restored mineralisation, blocking the activity of the BMP 
antagonists secreted by IVD cells.
 It is possible that the BMP antagonists secreted by IVD 
cells are responsible for spinal non-unions. The inhibition 
of BMP antagonists with L51P may result in an efficient 
and more physiological osteoinduction rather than delivery 
of exogenous osteogenic factors. Therefore, L51P might 
represent an attractive therapeutic candidate for bone 
healing.
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Introduction
The intervertebral disc (IVD) is an avascular tissue with 
nearly absent self-healing potential. Disc degeneration 
represents a major cause of chronic back pain and is 
associated with economic and social burdens (Balagué 
et al., 2012; Hoy et al., 2014; Dagenais et al., 2008). At 
some stage of their life, back pain has affected about 80 % 
of adults’ population. Current surgical treatments aim 
to repair the damaged disc replacing the injured tissue 
with a functional biological substitute, prosthesis or with 
fusion of the painful segments. Spinal interbody fusion 
is a surgical technique used to join two or more vertebral 
bodies replacing the IVD tissue with a cage filled with a 
bone autograft or allograft or a bone substitute, generally 
with the support of osteoinductive growth factors. Primary 
stability is achieved with the use of pedicle screw-based 
instrumentation, lateral or anterior plating systems, or 
direct fixation with screws, anchored within the cage. 
While the feasibility and benefits of interbody fusion have 
been recognised, removal of disc tissue is time consuming 
and, especially in case of minimally invasive surgical 
techniques, is often incomplete (Watkins et al., 2014).
 It has been suggested that partial removal of the disc 
results in a delayed and incomplete spinal fusion, requiring 
therefore reoperation (Osterman et al., 2003; Malter et al., 
1998; Watkins et al., 2014). From a clinical observation, 
the presence of nucleus pulposus (NP) tissue seems to 
alter the ossification process (McAfee et al., 2002) and 
a spinal non-union was reported in up to 20-40 % of the 
cases (Turner et al., 1992; Lee et al., 2011). Li et al. (2002) 
reported a delayed fusion of the spine of a porcine animal 
model in the presence of NP tissue within the disc space 
after spinal fusion surgery. However, the exact mechanism 
by which IVD cells and tissues hinder the ossification of 
the spine remains unknown.
 The IVD is composed of an inner NP surrounded by 
the annulus fibrosus (AF) tissue and hyaline-like articular 
cartilage is located at the endplates between the IVD and 
the vertebral bodies. Bone morphogenetic proteins (BMP) 
signalling is required for spinal and joint formation and 
alteration within this pathway results in skeletal diseases 
(Yanagita, 2005; Salazar et al., 2016). BMP signalling 
molecules, originally discovered for their ability to induce 
bone and cartilage formation, contribute to the development 
of various tissues during embryonic determination and 
adult tissue homeostasis, such as maintenance of joint 
integrity and repair of long bone fractures (Tsuji et al., 
2006).
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 BMP signalling molecules belong to the transforming 
growth factor β (TGFβ) superfamily. Ligands of the 
BMP initiate specific signalling cascades binding the 
cell surface receptors type I and type II BMP serine/
threonine kinase receptors (BMPR1 and BMPR2). 
Within the heterotetrameric formed complex, BMPR2 
phosphorylates BMPR1 and the signal is propagated 
by phosphorylation of the transcription factor SMAD1 
(SMA and mothers against decapentaplegic homolog 
1), SMAD5 and SMAD8 (Rahman et al., 2015). BMP 
signal transduction is tightly regulated by intracellular 
mediators and extracellular binding proteins, recognised 
as BMP antagonists. These antagonists function through 
direct association with BMP ligands, thus prohibiting 
BMP from binding their cognate receptors (Walsh et 
al., 2010). BMP antagonists, including Noggin (NOG), 
Chordin (CHRD) and the DAN (differential screening-
selected gene aberrative in neuroblastoma) family play 
a pivotal role in skeletogenesis and maintenance of adult 
tissue homeostasis (Stafford et al., 2011; Wijgerde et al., 
2005; Wu et al., 2016). For instance, it has been shown 
that NOG is an essential mediator for joint formation and 
NOG-mediated antagonism of BMP signalling is required 
for normal patterning (McMahon et al., 1998). While 
the importance of the BMP signalling molecules in axial 
skeleton development was previously reported, little is 
known about their contribution in adult IVD homeostasis. 
Thus, in order to improve spinal fusion surgery, it is 
important to investigate the role of BMP antagonists that 
are likely produced by IVD cells and might regulate bone 
formation and differentiation potential of mesenchymal 
stem cells to osteoprogenitor cells. For instance, the 
expression of BMP antagonists is increased during fracture 
healing and distraction osteogenesis (Kloen et al., 2012; 
Dean et al., 2010; Haque et al., 2008). Similarly, it is 
hypothesised that BMP antagonists, such as NOG and 
DAN family, are responsible for the reported spinal non-
union, although recombinant human BMP2 (rhBMP2) and 
rhBMP7 are administered in the orthopaedics in very high 
doses (Govender et al., 2002; Friedlaender et al., 2001; 
Haid et al., 2004) probably to compensate for the inhibitory 
activity of the BMP antagonists. In a clinical setting, 
inactivating these antagonists may represent a better 
therapeutic option to enhance bone regeneration, rather 
than the administration of excessive and non-physiological 
concentrations of BMPs that also raises safety issues 
(Carragee et al., 2012). The synthesis of an engineered 
BMP2 variant called L51P with a substitution of leucine 
to proline at codon position 51 was previously reported 
(Keller et al., 2004). L51P is deficient in type I receptor 
binding, whereas it maintains its affinity binding to type 
II receptors and modular proteins including NOG, CHRD 
and DAN family. These modifications convert the BMP2 
variant L51P into a receptor-inactive inhibitor of BMP 
antagonists. Importantly, L51P blocks the inhibitory action 
of endogenously expressed BMP antagonists, such as 
NOG, increases binding of BMP ligands to BMP receptors 
and restores the induction of osteogenesis. For instance, 
inhibition of endogenously expressed BMP antagonists 
with L51P increases bone healing in a rat femoral defect 
and reduces the demand for exogenous BMP2 (Sebald et 
al., 2012).
 Recently, we showed in an in vitro coculture 
system for spinal fusion that IVD cells inhibit the 
osteogenic differentiation potential of bone marrow-
derived mesenchymal stromal cells (MSC) (Chan et al., 
2015). Within this study, we aimed to understand the 
contribution of possibly involved BMP signalling pathways 
during ossification, with a focus on BMP antagonists. 
We determined the endogenous expression levels of the 
major BMP antagonists in IVD cells. Then, we assessed 
the effect of measured levels of BMP antagonists on 
osteogenesis. Subsequently, we investigated whether 
L51P-mediated neutralisation of BMP antagonists might 
improve the ossification of human osteoblasts precursor 
cells in the presence of IVD cells in a novel coculture 
Bone marrow aspirates IVD tissues
Coculture 
experiment
MSC 
donor
Patient 
birth Sex
IVD 
donor Level
Patient 
birth Sex Type
1 1 1931 f 1 L1-L2 1968 m T
2 2 1995 m 2 L4-L5 1959 m SD
3 2 1995 m 3 L1-L2 1982 m SD
4 3 1986 f 4 L5-S1 1958 m T
5 4 1958 m 5 L1-L2 1975 m TD
6 4 1958 m 6 L3-L4 1957 f TD
7 5 1957 f 7 L1-L2 1975 m TD
8 5 1957 f 8 L3-L4 1957 f TD
Table 1.Patients donor list of bone marrow aspirates and intervertebral disc (IVD) tissues for the coculture 
experiments. The bone marrow aspirates were obtained from 8 vertebral bodies of patients aged 48 ± 24.8 
years (mean ± SD) and 8 IVD tissues were collected from patients aged 47 ± 10.4 (mean ± SD). f female, m 
male, L lumbar vertebrae, S sacral, T trauma, SD symptomatic degenerative disc, TD trauma degenerative.
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system. Understanding the contribution of BMP signalling 
components to bone regeneration of the spine is of a central 
importance as it may provide therapeutical targets for an 
improved spinal fusion.
Materials and Methods
Human materials
Human bone marrow aspirates and IVD tissues were 
collected from patients undergoing spinal fusion surgery. 
The procedure was performed with patient’s written 
consent and the synopsis was approved by the ethical 
committee of the canton of Bern. The disc materials were 
harvested from patients undergoing surgery for painful, 
degenerated discs (SD, n = 2), trauma patients with healthy 
discs (T, n = 2) and degenerated non-symptomatic trauma 
discs (TD, n = 4) for the coculture experiments (Table 1). 
16 additional human discs (SD = 3; T = 2 and TD = 11) 
were used for the determination of expression of IVD 
endogenous BMP antagonists by gene expression analysis, 
immunocytochemistry, flow cytometry and conditioned 
media analysis (Table 2).
Cell isolation
Mononuclear cell fractions from bone marrow samples 
were isolated by gradient centrifugation (Histopaque 1077, 
Sigma-Aldrich, Buchs, Switzerland) and then seeded in 
basal medium consisting of Alpha minimum Essential 
Medium (α-MEM) containing 10 % foetal bovine serum 
(FBS, Sigma-Aldrich), penicillin/streptomycin (P/S, 
100 U/mL and 100 μg/mL, respectively, Merck, Darmstadt, 
Germany) and 2.5 ng/mL fibroblast growth factor 2 
(FGF2, Peprotech, London, UK) (Solchaga et al., 2005). 
The MSC were expanded in monolayer cultures for up to 
three passages, in order to purify the cell population and 
increase their yield. Cells were cryopreserved at −150 °C 
for further experiments. IVD tissue samples were divided 
into AF and NP by an experienced surgeon and processed 
within 24 h after the surgery. Disc-derived cells were 
isolated by sequential digestion of IVD tissues with 
1.9 mg/mL pronase (Roche, Basel, Switzerland) for 1 h 
and collagenase II (64 U/mL for NP and 129 U/mL for AF, 
Worthington, London, UK) at 37 °C overnight on a plate 
shaker (Lee et al., 2015). The remaining undigested tissue 
debris was removed by filtration through 100 µm strainer 
(Falcon, Becton Dickinson, Allschwil, Switzerland) 
and subsequently the cell viability was determined by 
trypan blue exclusion. The IVD cells were expanded in a 
proliferation medium (Dulbecco’s Modified Eagle Medium 
[DMEM] containing 10 % FBS and P/S) until confluency 
and processed for the coculture experiments.
Cell and alginate coculture
MSC were seeded at a density of 20 × 103 cells/well in 
12-well plates in the basal medium and left overnight 
for cell adherence. AF cells (AFC) and NP cells (NPC) 
were mixed separately in 1.2 % alginate solution (Fluka, 
Basel, Switzerland) at a density of 4 millions/mL. The 
suspensions were dropped through a 22-G needle into a 
102 mM CaCl2 and 0.9 % NaCl to form the alginate beads 
(~ 25 µL droplets). The alginate beads (6 beads/well) were 
transferred to indirect culture inserts (0.4 µm pore size, 
Becton Dickinson, Brussels, Belgium) with previously 
seeded MSC and the cultures were conducted in osteogenic 
medium (α-MEM containing 10 % FBS, P/S, 100 nM 
Table 2. Patients donor list 
of intervertebral disc (IVD) 
tissues for the determination 
of BMP antagonists. The 
bone marrow aspirates were 
obtained from 16 IVD tissues 
from patients aged 39 ± 16.6 
years (mean ± SD). f female, 
m male, L lumbar vertebrae, S 
sacral, T thoracic, C cervical, 
T trauma, SD symptomatic 
degenerative disc, TD trauma 
degenerative.
IVD donor Level Patient birth Sex Type
1 L4-L5 1959 m SD
2 T12-L1 1968 m TD
3 L1-L2 1968 m TD
4 T12-L1 1982 m TD
5 L5-S1 1958 m TD
6 L2-L3 1997 f TD
7 T12-L1 1992 f TD
8 T12-L1 1956 f TD
9 L4-L5 1966 f SD
10 T12-L1 1999 m TD
11 L2-L3 2001 m TD
12 L3-L4 1979 m TD
13 L2-L3 1966 m TD
14 C6-C7 1977 f SD
15 L1-L2 1997 m T
16 T12-L1 1999 m T
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dexamethasone, 10 mM β-glycerophosphate and 0.05 mM 
L-ascorbic acid-2-phosphate [all from Sigma-Aldrich]). In 
parallel, the same experimental set-up was conducted with 
the addition of L51P (100 ng/mL, synthesised and purified 
at the Department of Physiological Chemistry, University 
of Würzburg, Germany) to the cultures. Positive control 
group represented MSC coculture with empty alginate 
beads in osteogenic medium. MSC cultured in basal 
medium served as negative control group (Fig. 1). The 
control and experimental groups were maintained in culture 
for 21 d with medium refreshed twice a week.
Analysis of gene expression
Total RNA was extracted as previously described (May 
et al., 2017) from MSC after coculture and bone-related 
genes, including alkaline phosphatase (ALP), runt-
related transcription factor 2 (RUNX2), alpha-2 chain of 
collagen type I (COL1A2), osteopontin (OPN), osteocalcin 
(official name is bone gamma-carboxyglutamic acid-
containing protein, BGLAP) and the ribosomal 18S RNA 
as reference gene, were determined. The average cycle 
number of 18S accounted for 12.1 ± 0.49 (mean ± standard 
deviation [SD]) among individual treatment groups. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) 
was monitored as a second reference gene and accounted 
for 16.7 ± 0.63 (mean ± SD) cycles. The expression of 
BMP antagonists, including GREM1, NOG and CHRD was 
determined in passage one AFC and NPC. Human-specific 
oligonucleotide primers (Table 3) (Microsynth, Balgach, 
Switzerland) were designed with Beacon DesignerTM 
software (Premier Biosoft, California, Palo Alto, USA) 
based on nucleotide sequences from GenBank. The primers 
were tested for efficiency and melting curves of amplicons 
were performed to determine specific amplification. 
Relative gene expression was determined by application of 
a threshold cycle and normalised to control MSC on day 0 
using the 2-ΔΔCt method according to Livak and Schmittgen 
(Livak and Schmittgen, 2001).
Flow cytometry
To assess intracellular BMP antagonists, IVD cells from 
passage one were permeabilised as previously described 
(Flagler et al., 2009). Briefly, 20 × 103 cells in 100 μL of 
phosphate buffered saline (PBS) + 2 % FBS were mixed 
with 1 mL ice cold methanol (−20 °C) and incubated for 
15 min on ice. After washing, the cells were incubated with 
a mouse anti-human NOG (1 µg/mL, clone 1H8, Sigma-
Aldrich), rabbit anti-human GREM1 (1 µg/mL, sc-28873, 
Santa Cruz, Dallas, TX, USA) and goat anti-human CHRD 
(1 µg/mL, sc-18265, Santa Cruz) antibodies for 15 min 
at room temperature. Incubation for further 15 min with 
the appropriate secondary antibodies was conducted for 
detection of antibody binding. NOG antibody was labelled 
with the Alexa Fluor 555 goat anti-mouse, GREM1 with 
the Alexa Fluor 488 goat anti-rabbit and CHRD with the 
Alexa Fluor 555 rabbit anti-goat (10 μg/mL, all from 
Thermo Fisher Scientific, Basel, Switzerland, Table 4). 
Isotype-matched antibodies (Thermo Fisher Scientific) 
were used as negative controls. Fluorescence was measured 
on a LSRII flow cytometry system (Becton Dickinson) and 
the data were analysed using FlowJo Software (version 
10.1 for MacOS X; LLC, Ashland, OR, USA).
Immunocytochemistry
AFC and NPC from passage one were seeded on coverslips 
in 6-well plates at a density of 50 × 103 cells/well in the 
proliferation medium. The cells were harvested after 
48 h, fixed with 4 % formaldehyde solution for 10 min 
Fig. 1. Experimental design for the coculture experiments. Human bone marrow-derived mesenchymal stromal 
cells (MSC) were seeded in 12-well plates and cultured using indirect coculture inserts with nucleus pulposus 
cells (NPC) and annulus fibrosus cells (AFC) embedded in alginate beads supplemented with medium containing 
osteogenic factors. The experimental setup was replicated by addition of L51P (100 ng/mL) to the cocultures. 
Positive control group represents MSC cultured with empty alginate beads in medium containing osteogenic factors 
and negative control group was MSC cultured in basal medium (without osteogenic factors).
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and analysed with immunocytochemistry staining. 
Alternatively, the IVD cells were stored in PBS at 4 °C 
until further analysis. The cells were permeabilised with 
100 % methanol for 2 min, blocked with 10 % FBS for 
1 h and subsequently incubated overnight at 4 °C with 
the primary human antibodies against GREM1, NOG and 
CHRD (1 µg/mL) diluted in PBS + 0.5 % bovine serum 
albumin (BSA, Sigma-Aldrich). The IVD cells were either 
subjected to a double labelling with NOG and GREM1 
or single staining with CHRD. After thoroughly washing 
with PBS, incubation was conducted with the appropriate 
secondary antibody (Table 4) for 1 h. The coverslips 
were mounted in SlowFade® gold antifade reagent with 
4’,6-diamidino-2-phenylindole (DAPI, Thermo Fisher 
Scientific) and the antibodies binding was visualised with a 
confocal laser scanning microscope (cLSM710, Carl Zeiss, 
Jena, Germany) with a 40× magnification immersed in oil.
Conditioned medium and quantification of BMP 
antagonists by ELISA
In order to generate the conditioned medium, AFC and NPC 
(passage one) were encapsulated in 1.2 % alginate beads 
(4 millions/mL), transferred to 12-well plates (6 beads/
well) and cultured for 4 d in the proliferation medium. The 
medium was filtered, centrifuged at 1000 × g for 20 min 
and the supernatant was collected and stored at −20 °C. The 
secreted BMP antagonists were measured in the collected 
medium using the human GREM1, NOG and CHRD 
detection kits (Clone Cloud-Clone corp., SEC128Hu, 
SEC130Mi and SEC126Hu, respectively, Houston, TX, 
USA) following the manufacturer’s instructions.
Alkaline phosphatase (ALP) activity
After 21 d of osteogenic differentiation, the MSC layers 
were washed with tris-buffered saline, lysed using CelLytic 
(Sigma-Aldrich) and homogenised by sonication (2 × 7 s). 
ALP was determined using the phosphatase assay kit 
(Sigma-Aldrich) with the instructions of the manufacturer. 
Briefly, the cells were transferred into 96-well plates and 
incubated with the p-nitrophenylphosphatase substrate 
at 37 °C. The reaction was stopped after 30 min and 
the formed complex was measured at 405 nm on a 
microplate reader (SpectraMax M5, Bucher Biotec, Basel, 
Switzerland).
 To assess the effect of detected concentrations (by 
ELISA assay) of IVD cells’ secreted BMP antagonists 
on osteogenic differentiation, MSC were cultured for 7 d 
in osteogenic medium supplemented with recombinant 
GREM1 (2 ng/mL, Peprotech) and NOG (1 ng/mL) either 
alone or in combination and harvested for ALP activity. 
Positive and negative groups (MSC cultured in osteogenic 
medium and basal medium, respectively) were included as 
controls.
Gene Forward sequence Reverse sequence
18S CGA TGC GGC GGC GTT ATT C TCT GTC AAT CCT GTC CGT GTC C
GAPDH ATC TTC CAG GAG CGA GAT GGA GGC ATT GCT GAT GAT
ALP GTA TGAG AGT GAC GAG AA AAT AGG TAG TCC ACA TTG T
RUNX2 AGC AGC ACT CCA TAT CTC T TTC CAT CAG CGT CAA CAC
COL1A2 GTGGCAGTGATGGAAGTG CACCAGTAAGGCCGTTTG
OPN ACG CCG ACC AAG GAA AAC TC GTC CAT AAA CCA CAC TAT CAC CTC G
BGLAP GCA GAG TCC AGC AAA GGT G CCA GCC ATT GAT ACA GGT AGC
GREM1 GAG AAG ACG ACG AGA GTA AGG AA CCA ACC AGT AGC AGA TGA ACA G
NOG CAG CAC TAT CTC CAC ATC CG CAG CAG CGT CTC GTT CAG
CHRD GCC TCC GCT TCT CTA TCT AAC AGG ACA CTG CCA TTG
Table 3. Custom-designed human DNA primers used for real-time qPCR study. Amplicons were generated 
using a 2-step amplification cycling (95 °C for 15 s and 61 °C for 30 s for 45 cycles) and SYBR-green 
mastermix.
Table 4. Overview of antibodies used to detect BMP antagonists in human IVD cells.
Protein Type and Class Host Species Dilution Catalog Number Company
Primary Antibodies
Chordin polyclonal, IgG goat 1:200 chordin (N-20): 
sc-18265
Santa Cruz
Gremlin1 polyclonal, IgG rabbit 1:200 sc-28873 Santa Cruz
Noggin monoclonal, IgG2b mouse 1:200 SAB3300029 Sigma-Aldrich
Secondary Antibodies
Alexa Fluor® 488 polyclonal, IgG goat anti-rabbit 1:200 A-11008 Fisher Thermo Scientific
Alexa Fluor® 555 polyclonal, IgG2b goat anti-mouse 1:200 A-21147 Fisher Thermo Scientific
Alexa Fluor® 555 polyclonal, IgG rabbit anti-goat 1:200 A-21431 Fisher Thermo Scientific
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Histology of mineralised matrix
The mineralised matrix in MSC was detected using alizarin 
red staining. The cell layer was fixed in 4 % formaldehyde 
solution, rinsed with distilled water and subsequently 
exposed to 2 % alizarin red solution (Sigma-Aldrich) for 
45 min. The alizarin red staining was released from the 
cell layer by addition of 10 % cetylpyridinium chloride 
solution (Sigma-Aldrich) into the wells and incubation 
for 1 h while vigorously shacked. The samples were 
diluted 10-fold, transferred to 96-wells and subsequently 
the absorbance was measured at 570 nm with an ELISA 
reader (SpectraMax M5).
XTT assay
IVD cells (and MSC) were seeded in 96-well plates at a 
density of 2 × 103 cells/well and grown in the proliferation 
medium supplemented with L51P at concentrations of 
0, 10, 25, 50, 100, 250, 500 and 1,000 ng/mL. On day 
three, the XTT assay (Cell Proliferation kit II, Roche 
Diagnostics, Rotkreuz, Switzerland) was performed to 
measure cells viability, according to the manufacturer’s 
recommendations. Briefly, the cells were incubated 
with 50 µL XTT labelling mixture/well in a humidified 
atmosphere (5 % CO2, 37 °C) for 3 h. The absorbance was 
measured at 490 nm (SpectraMax M5).
Statistics
Differences in the ELISA, ALP activity and levels of 
transcripts were evaluated by Student’s t-test; differences 
in the alizarin red staining and XTT by one-way ANOVA 
with Bonferroni’s post-hoc test after testing the data for 
normal distribution, using GraphPad Prism (version 6.0h 
for Mac OS; GraphPad Software Inc., La Jolla, CA USA). 
p < 0.05 was considered significant.
Results
Endogenous disc-derived BMP antagonists
To investigate the endogenous expression of major 
BMP antagonists by IVD cells, transcripts and protein 
levels of GREM1, NOG and CHRD were determined. 
Gene expression analysis revealed expression of major 
BMP antagonists by both AFC and NPC (Fig. 2a), with 
abundance in NPC, although not significant (p = 0.42, 
p = 0.65, and p = 0.72 for GREM1, NOG and CHRD, 
respectively). Similar results were observed with 
immunocytochemistry: IVD cells stained positive for 
GREM1 and NOG with an intense staining detected in NPC 
(Fig. 2c). CHRD immunocytochemistry staining revealed 
a nuclear localisation and was equally detected in both 
Fig. 2. The expression of endogenous bone morphogenetic proteins (BMP) antagonists by intervertebral disc cells 
(IVD). The expression of major BMP antagonists, i.e. Gremlin1, Noggin and Chordin was assessed in passage one 
nucleus pulposus cells (NPC) and annulus fibrosus cells (AFC) by (a) real-time quantitative PCR, (b) flow cytometry 
(intracellular staining and compared to the isotype controls), (c) immunocytochemistry and (d) ELISA (conditioned 
medium). An abundance of the BMP antagonists was detected by NPC. Values are expressed as means ± SD (n = 5).
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Fig. 3. The expression of alkaline phosphatase (ALP) activity in MSC. (a) MSC were cultured in osteogenic 
medium (positive control), coculture with nucleus pulposus cells (NPC) and annulus fibrosus cells (AFC) with and 
without L51P and cultured in basal medium (without osteogenic factors, negative control) for 21 d. The ALP activity 
decreased in MSC in the presence of NPC and addition of L51P to the cocultures resulted in a pronounced decrease 
of ALP. Values are represented as means ± SD (n = 11). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001 
compared to the positive control group. # p < 0.05 compared to coculture with NPC or AFC. (b) MSC were cultured 
in osteogenic medium supplemented with recombinant Gremlin1 (2 ng/mL) and Noggin (1 ng/mL) for 7 d. Positive 
control group was MSC in osteogenic medium and negative control represented MSC cultured in basal medium. 
Gremlin1 either alone or in combination with Noggin reduced the ALP activity of MSC. * p < 0.05, ** p < 0.01, 
*** p < 0.001 compared to the positive control group. # p < 0.05 compared to negative control group.
Fig. 4. Gene expression of bone-related markers, i.e. alkaline phosphatase (ALP), runt-related transcription factor 
2 (RUNX2), alpha-2 chain of collagen type I (COL1A2), osteopontin (OPN) and osteocalcin (BGLAP) in MSC. 
MSC were cultured in osteogenic medium (positive control), coculture with nucleus pulposus cells (NPC) and 
annulus fibrosus cells (AFC) with and without L51P and cultured in basal medium (without osteogenic factors, 
negative control). A general reduction of bone-related markers was observed in MSC, when cocultured with NPC 
and AFC, and L51P increased the expression of RUNX2, COL1A2 and OPN to levels similar to positive control 
group. ALP was reduced when L51P was added to the cocultures with NPC. Values are expressed as means ± SD 
(n = 6). * p < 0.05, ** p < 0.01, *** p < 0.001 compared to the positive control group. # p < 0.05 compared to 
culture with NPC or AFC.
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IVD cells (Fig. 2c). By flow cytometry, variable protein 
levels of intracellular BMP antagonists were detectable in 
permeabilised AFC and NPC, resulting more abundant in 
NPC (Fig. 2b). The fraction of positive NPC expressing 
GREM1, NOG and CHRD accounted for 14.3 ± 5.39 %, 
7.41 ± 2.72 % and 5.3 ± 3.93 % (values presented as mean 
± SD), respectively. The ratios of NPC to AFC positive for 
GREM1, NOG and CHRD accounted for 2.97 ± 0.65 %, 
1.37 ± 0.51 % and 1.02 ± 0.76 %, respectively. The BMP 
antagonists were detectable in the conditioned medium 
with levels between 0.30 ± 0.17 and 2.10 ± 0.52 ng/mL. An 
abundance in GREM1 was observed in NPC (p = 0.0022, 
Fig. 2d). The ratios of NPC to AFC for GREM1, NOG and 
CHRD levels were 2.90 ± 1.66, 1.96 ± 1.46 and 1.35 ± 0.87, 
respectively.
ALP activity
After 21 d of osteogenic differentiation, ALP activity 
was measured in MSC cocultured with IVD cells 
in osteogenic medium and in basal medium groups. 
ALP activity in the osteogenic differentiation medium 
(positive control) accounted for 373.1 ± 67.3 mU/mL 
and increased significantly as compared to MSC cultured 
in the basal medium (negative control 77.6 ± 41.5 mU/
mL, p < 0.0001) (Fig. 3a). Coculture of MSC with NPC 
resulted in a significant decrease of ALP activity (p = 0.03) 
and coculture of MSC with AFC did not differ from the 
positive control group. It was noted that L51P added to 
the cocultures caused a general reduction in ALP activity 
in all experimental groups as compared to the positive 
control group (p = 0.0003 in NPC and p = 0.015 in AFC, 
respectively). In addition, cocultures of MSC and NPC with 
L51P resulted in a decrease of ALP activity as compared 
to coculture of MSC with NPC alone (p = 0.024).
 Recombinant GREM1 and NOG (2 ng/mL and 1 ng/
mL, respectively, concentrations as detected by ELISA 
assay in IVD cells) added to the cultures of MSC, alone 
or in combinations, significantly reduced ALP activity 
as compared to positive control group (p = 0.010 and 
p = 0.005, respectively, Fig. 3b). However, NOG (1 ng/mL) 
alone did not decrease ALP activity of MSC (p = 0.131).
Gene expression
Similarly to ALP protein level, ALP transcript level was 
higher in positive control and decreased in coculture 
of MSC with either NPC or AFC, to levels comparable 
to negative control (Fig. 4). Addition of L51P, in MSC 
cocultured with NPC, reduced ALP, although not 
significantly (p = 0.96). Similar result was observed in 
coculture of MSC with AFC. Relative gene expression 
of bone-related markers showed higher expression in 
positive control than in negative control. Gene expression 
of RUNX2, OPN and BGLAP in MSC cocultured with 
IVD cells was comparable to negative control. Addition 
of L51P to the cocultures of MSC with IVD cells resulted 
in a significant increase, to levels comparable to positive 
control, of RUNX2 (p = 0.033 for NPC and p = 0.009 for 
AFC), OPN (p = 0.035 for NPC and p = 0.001 for AFC) 
and COL1A2 (p = 0.026 for NPC and p = 0.027 for AFC) 
as compared to L51P-untreated cocultures.
L51P and proliferation
To exclude the possibility that either a cytotoxic effect 
and/or inhibition of proliferation induced by L51P may 
contribute to the alteration of IVD cells’ phenotype and 
interact with MSC differentiation, an XTT assay was 
performed. Up to a concentration of 1,000 ng/mL no 
significant change in the number of viable IVD cells was 
observed (Fig. 5), suggesting that L51P is not cytotoxic 
and does not interfere with cell proliferation and metabolic 
activity. Similarly, L51P up to 1,000 ng/mL did not induce 
any cytotoxic effect on MSC (data not shown).
Histology of mineralised matrix
After three weeks of osteogenic induction in osteogenic 
differentiation medium (positive control), the MSC 
deposited an extensive mineralised matrix, as demonstrated 
by an intense alizarin red staining (Fig. 6a). However, 
MSC cultured in the basal medium (negative control) 
were negative for alizarin red and no calcium deposition 
was observed. Coculture of MSC with either NPC or AFC 
resulted in a strong reduction of mineralisation, with results 
comparable to the negative control (p > 0.99, Fig. 6b). 
The addition of L51P to the cocultures of MSC with NPC 
and AFC reversed the inhibitory effect of IVD cells and 
resulted in an increased calcium deposition (p = 0.0002 and 
p = 0.0041 in NPC and AFC), with results comparable to 
the positive control group (p = 0.37 and p > 0.99 in NPC 
and AFC, respectively).
Fig. 5. Effect of L51P on the intervertebral 
disc cells metabolic activity. L51P added to 
the culture of nucleus pulposus cells (NPC) 
and annulus fibrosus cells (AFC) for 3 d did 
not affect the number of viable intervertebral 
disc cells as detected by XTT assay. Values are 
represented as means ± SD (n = 5).
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Discussion
Spinal interbody fusion, although being the gold standard 
treatment for many spinal disorders, results in a non-
union rate of up to 30 % of the cases (Watkins et al., 
2014). Clinical observations suggested that the presence 
of remaining IVD tissues during spinal fusion surgery 
might hamper the ossification process of spinal vertebras, 
resulting in a delayed and incomplete interbody fusion. 
Along with this observation, an experimental study 
performed on porcine animal model showed a fusion 
rate of only 10 % when the autograft applied in the disc 
space was mixed with NP tissue, while the bridging rate 
increased to 70 % when a pure autograft was used (Li et 
al., 2002). We previously reported that IVD cells hinder 
the osteogenic differentiation of MSC in an in vitro 
coculture system (Chan et al., 2015). However, the exact 
mechanism by which the disc cells inhibit bone formation 
remains not fully understood. RhBMP2 has been used in 
the clinics to accelerate and augment bone regeneration in 
bone fractures, long bones non-union and spinal fusion. 
Although promising clinical trials, the growth factor has to 
be applied at levels that exceed those of naturally occurring 
BMP2 present in 1,000 kg of bone tissue to induce 
sufficient bone formation (Urist et al., 1979; Govender 
et al., 2002; Boden et al., 2002). This raises the concerns 
regarding costs, safety issues and also complications 
associated with rhBMP2 leading to ectopic bone and cyst 
formation (Tannoury and An, 2014; Zara et al., 2011).
 While the importance of BMP antagonists, including 
NOG, GREM1, CHRD and twisted gastrulation was 
previously described in joint development, bone 
remodelling and fracture healing (Wijgerde et al., 2005; 
Khokha et al., 2003; Brunet et al., 1998; Zakin and De 
Robertis, 2004; Abe2006; Fisher and Halpern, 1999; Wu 
et al., 2003; Dean et al., 2010; Yoshimura et al., 2001), 
their contributions in IVD is not yet fully understood.
 Within this study, we aimed to investigate the role of 
BMP signalling within the spine microenvironment in 
spinal fusion by determining the expression of endogenous 
Fig. 6. Osteogenesis of bone marrow-derived mesenchymal stromal cells. MSC were cultured in osteogenic 
medium (positive control), cocultured with nucleus pulsposus cells (NPC) and annulus fibrosus cells (AFC) with 
and without L51P or cultured in basal medium (without osteogenic factors, negative control). (a) Macroscopic and 
microscopic images of osteogenesis (alizarin red staining) and (b) the corresponding quantification. The osteogenic 
differentiation of MSC was potentially altered by NPC and AFC with results similar to the negative control group. 
However, addition of L51P restored mineralisation to levels similar to positive control (p = 0.15 in coculture 
with NPC and p = 0.90 in coculture with AFC). Values are shown as means ± SD (n = 4). * p < 0.05, ** p < 0.01, 
*** p < 0.001, **** p < 0.0001 compared to the positive control group. # p < 0.05, ## p < 0.05, ### p < 0.01 compared 
to coculture with NPC or AFC.
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disc cells-derived BMP antagonists. We could confirm 
that IVD cells secrete the major BMP antagonists, namely 
NOG, GREM1 and CHRD with abundance in NPC with 
up to 2 ng/mL, a concentration shown to prevent the 
osteogenic differentiation potential of MSC (our study) 
and osteoblasts differentiation (Wu et al., 2003). CHRD 
synthesised by IVD cells accumulates in the vertebral 
body of mouse embryo (Zakin et al., 2010). In addition, 
a recent study reported a loss of CHRD expression with 
degeneration of the IVD, suggesting the potential use of 
CHRD as a marker for healthy disc phenotype (Minogue 
et al., 2008).
 It is of interest that GREM1 was also found differently 
regulated in our donor-matched NP versus AF samples 
at the transcript and protein level. GREM1 was found 
significantly dysregulated in a recent microarray study 
comparing the transcriptome of AF tissues between 
degenerated and non-degenerated patients (Kazezian et 
al., 2015). This indicates that GREM1 could be regulated 
by increased disc degeneration. However, this study did 
not compare NP and AF expression of the same donor.
 BMP antagonists could be determinant for healing, 
incomplete or even failure of bone regeneration. Several 
attempts to enhance bone healing by suppression of 
BMP antagonists were described. Wan et al. showed that 
NOG suppression by small interfering RNA (siRNA) 
in MC3T3-T1 cells and mice calvarial osteoblasts 
enhanced the cells osteogenic differentiation potential. 
In addition, NOG siRNA-transfected osteoblasts, that 
were implemented in murine calvarial critical size 
defect, accelerated bone regeneration as compared to 
control osteoblasts (Wan et al., 2007). Similarly, CHRD 
knockdown by siRNA accelerates the differentiation 
of MSC towards the osteoblastic lineage and leads to 
increased deposition of minerals in vitro (Kwong et al., 
2008). In addition, in mice, conditional deletion of GREM1 
under the control of the bone-specific osteocalcin promoter 
enhanced osteoblastic activity and led to increased 
trabecular bone volume (Gazzerro et al., 2007).
 To further understand the role of BMP signalling in 
spinal fusion, we aimed to investigate the contribution 
of the IVD cells’ secreted BMP antagonists for spinal 
fusion and inhibition of osteogenic differentiation of 
osteoprecursor cells. Therefore, we targeted the BMP 
antagonists by addition of the BMP2 variant L51P to 
the cocultures of MSC and IVD cells. We showed that 
L51P could salvage the osteogenic differentiation of 
MSC in the presence of IVD cells as evidenced by 
transcripts and protein levels. To address the regulation 
of osteoblast formation, we determined the transcription 
factors RUNX2, ALP, COL1A2, osteopontin (OPN) 
and osteocalcin (BGLAP). The latter two have been 
commonly used as early and late markers of osteogenic 
differentiation. Our data revealed an increase of bone-
related markers of MSC in the presence of L51P suggesting 
their differentiation towards the osteoblastic lineage. 
Albers et al. (2012) reported an enhanced BGLAP gene 
expression in culture of primary murine osteoblasts with 
L51P. Similarly, Khattab et al. (2014) detected an increase 
of the osteoblast-specific transcription factor in the MC3T3 
osteoblastic cell line by addition of L51P. However, we 
found that L51P decreased the ALP gene expression of 
human MSC and these results were confirmed on the 
protein level by measuring the ALP activity after 21 d of 
culture. This observation could be attributed to the fact that 
ALP is an early marker of osteogenic differentiation. We 
found that in culture the ALP activity of MSC increases 
with a peak observed after 10 d and thereafter declines to 
the baseline levels by 21-28 d (data not shown). Along 
with this finding, it was previously reported that L51P 
decreases the ALP activity of terminally differentiated 
murine calvarial osteoblasts after 3 d of culture (Albers 
et al., 2012). The precise mechanism of inhibition of ALP 
activity by L51P remains not perceptible and needs to be 
further elucidated.
 To address the inhibitory effect of BMP antagonists 
on osteogenesis, we investigated by histology the ability 
of MSC to deposit calcium, as an outcome for bone 
formation in vitro. We found that IVD cells strongly 
inhibit the mineralisation of MSC, while L51P abolishes 
the IVD-mediated inhibition of osteogenic differentiation 
and leads to an intensive mineralisation potential. These 
finding confirmed that the IVD’s secreted BMP antagonists 
are responsible for inhibition of osteogenic differentiation 
of bone precursor cells.
 Current attempts to improve spinal fusion include the 
local administration of high concentrations of rhBMP2 
or rhBMP7 in the IVD space after disc removal in 
combination with cages (Carragee et al., 2011; Simmonds 
et al., 2013). The large demand of the growth factors is 
probably required to compensate for the presence of BMP 
antagonists secreted by the IVD cells. Recently, intradiscal 
application of rhBMP7 was administrated at a dose of 
250 µg per single canine disc and revealed, however, no 
IVD regeneration. Instead extensive bone formation was 
noticed (Willems et al., 2015).
 The inhibition of BMP antagonists represents a 
promising alternative to enhance bone regeneration. Sebald 
et al. (2012) showed that a combination of BMP2 and 
L51P (at 1 μg per scaffold) loaded β-tricalcium phosphate 
ceramics better promoted bone formation compared to 
BMP2, only in a critical size femur defect of rat model. 
These data suggested that L51P inhibits the action of 
BMP antagonists to regulate the signalling mediated by 
BMP2, without the requirement of adding large amounts 
of exogenous growth factors. Taking all together, the 
inhibition of BMP antagonists by L51P may result in a 
more efficient and physiological BMP signalling, rather 
than delivery of exogenous osteoinductive factors, such 
as BMP2. Therefore, this strategy represents an attractive 
treatment to induce bone healing.
 To the best of our knowledge, this is the first 
study reporting a protein-based approach to enhance 
osteoinduction of osteoprogenitor cells in the presence 
of IVD cells via inhibition of BMP antagonists. Besides 
understanding basic mechanisms of spinal non-union after 
discectomy, the current study suggests the potential use of 
factors antagonising disc-mediated BMP inhibitors, such 
as L51P, in order to increase bone regeneration in the disc 
niche.
 Future research should investigate into the central 
mediator(s) of bone formation in spinal fusion surgery. 
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Recently, it has been shown that BMP9-induced osteogenic 
differentiation of MSC is independent on NOG (Wang et 
al., 2013). Further, the role of the cartilaginous endplate 
cells in spinal fusion should be elucidated.
Conclusion
This study confirms a significant inhibition of osteogenic 
differentiation in osteoprogenitor cells in the presence of 
IVD cells and provides similar evidences in spinal non-
union. The mechanism is most likely due to an alteration of 
BMP signalling cascade caused by the IVD cells-mediated 
BMP antagonists. Furthermore, this study demonstrates 
that BMP signalling plays an important role in regulating 
bone formation and that antagonising the BMP inhibitors 
with L51P may improve the bioavailability of endogenous 
BMP to increase and accelerate bone formation. Future 
long-term animal studies will determine the suitability of 
the application of L51P as a therapeutic target to enhance 
bone regeneration in spinal fusion.
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Discussion with Reviewers
Laura Creemers: Are there any synthetic inhibitors of 
the antagonists that could be used to single out the actual 
mechanism of L51P induced restoration of mineralisation?
Authors: Besides L51P, we are not aware of other 
synthetic molecules that are commercially available and 
could be used with the aim to inhibit BMP antagonists. 
Instead, molecule-based techniques, such as suppression 
by small interfering RNA (siRNA), cognate antibody or 
conditional deletion could be used to address the effect of 
individual BMP antagonists (Ghadakzadeh et al., 2016). 
For instance, Noggin siRNA-transfected osteoblasts, 
that were implemented into calvarial critical size defect, 
showed enhanced bone regeneration as compared to control 
osteoblasts (Wan et al., 2007). Same results, using a similar 
knock-down approach, were achieved for adipose-derived 
MSCs (Fan et al., 2013). Similarly, blocking of Chordin 
by siRNA enhanced osteogenic differentiation of human 
mesenchymal stem cells and induced extracellular mineral 
deposition (Kwong et al., 2008).
Lisbet Haglund: What delivery system would the authors 
foresee being used for L51P clinical application?
Authors: Ideally, the scaffold applied for bone regeneration 
should provide biocompatibility, well-defined porosity, 
biodegradation rate and importantly the capability 
to control sustained growth factor release. Calcium 
phosphate-based materials, such as hydroxyapatite and 
tricalcium phosphate, represent well-established bone 
substitutes for orthopaedic clinical applications. However, 
to overcome the insufficient retention of the growth factors 
within the carrier biomaterial, high concentrations of the 
proteins are generally required, with adverse side effects 
including heterotopic ossification. Efficient and controlled 
delivery of growth factors from the carrier critically 
depends on their release kinetics.
 We propose L51P immobilised on β-tricalcium 
phosphate (β-TCP) ceramics with a calcium phosphate 
co-precipitation technique previously described (Choy et 
al., 2014; Wernike et al., 2010) for spinal fusion surgery, 
as well as for reconstruction of large bone defects. This 
modified form of local and sustained delivery system might 
allow a long-term release of the biologically active L51P 
into the surrounding extracellular matrix, possibly by cell-
mediated mechanism, such as the resorption activity of 
bone marrow cells differentiated into osteoclasts. Further, 
in vivo studies are needed to address the suitability of the 
β-TCP delivery system and the action of L51P on bone 
regeneration.
 In the case of partial discectomy for spinal fusion, 
L51P could be bound to the hydrogel-like system that 
enables slow growth factor release, such as a thermo-
reversible hydrogel (TR-HG), based on a modified 
polysaccharide with a thermo-reversible polyamide 
[poly(N-isopropylacrylamide)]. Such a hydrogel would 
have the advantage of easy delivery to the site by injection 
through a syringe and by fast gelation.
Lisbet Haglund: What is the half-life of L51P in culture 
media and, if known, in vivo?
Authors: We did not estimate the half-life of L51P in 
culture media, however, in an in vitro protein release assay, 
L51P was stable over a culture period of three weeks and 
was accumulated into the supernatant as detected by a 
BMP2 ELISA assay (Sebald et al., 2012). L51P loaded 
β-tricalcium phosphate ceramics with 1 μg or 10 μg per 
scaffold resulted in a burst release of 60 % of the total 
protein amount within the first 24 h with no difference in 
the relative protein release kinetics whether 1 μg or 10 μg 
was adsorbed. Further animal studies will determine the 
stability of L51P applied.
Lisbet Haglund: Does L51P affect viability and metabolic 
activity of connective tissue cells?
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Authors: Based on our results and previous studies 
(Albers et al., 2012), L51P added to the cultures does 
not affect the cell viability nor induce a cytotoxic effect 
on human intervertebral disc cells, human bone marrow-
derived mesenchymal stromal cells and murine calvarial 
osteoblasts.
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